immunon

This monoclonal antibody drug selectively targets TNF alpha

This monoclonal antibody drug selectively targets TNF alpha

Humira® (Adalimumab)

This drug targets the complement system by binding to the C5 protein

Ultomiris® (Ravulizumab)

This oral, small molecule drug targets the complement system

Fabhalta® (Iptacopan)

This monoclonal antibody targets both TNF alpha and TNF beta

Enbrel® (Etanercept)

True or False. Entanercept (Enbrel®) is not effective in diseases such as Inflammatory Bowel Disease and sarcoidosis.

True

This drug inhibits IL-6 signaling and can cause liver function abnormalities

Actemra® (Tocilizumab)

This drug is a recombinant form of IL-1RA made in E. coli and is known to penetrate the CSF.

Kineret® (Anakinra)

A drug that acts as a decoy receptor and therefore can bind IL-1 beta as well as IL-1 alpha and IL-1RA

Arcalyst® (Rilonacept)

A drug specific for blocking IL-1 beta

Ilaris® (Canakinumab)

A drug that targets IL-23 and also IL-12

Stelara® (Ustekinumab)

A drug that neutralizes both IL-23 and IL-39

Tremfya® (Guselkumab)

This drug selectively inhibits IL-17A

Cosentyx® (Secukinumab)

This drug is a dual inhibitor of IL-17A and IL-17F

Bimzelx® (Bimekizumab)

This drug inhibits the actions of IL-17 family members that signal through IL-17RA

Siliq® (Brodalumab)

This drug neutralizes the activity of soluble BLyS (also known as BAFF)

Benlysta® (Belimumab)